MedTrace Logo

Acute Exposure of High Altitude on Cardiac Output

NCT03637218 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2020-01-07

No results posted yet for this study

Summary

Randomized crossover trial in patients with Pulmonary Hypertension (PAH, CTEPH) to assess the acute response High Altitude (Säntis; 2500m above sea level) on non-invasive cardiac output assessments by Finapres® NOVA Technology at rest and under exercise

Conditions

  • Pulmonary Hypertension

Interventions

OTHER

Assessment at Low Altitude (470m above sea level)

Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure

OTHER

Exposure to High Altitude (2500m above sea level)

Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Silvia Ulrich, Prof. · University of Zurich

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-01
Primary Completion
2019-01-01
Completion
2019-01-01

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03637218 on ClinicalTrials.gov